ArticleAmerican journal of hypertension2022
Prevalence, Treatment, and Control of Hypertension Among US Women of Reproductive Age by Race/Hispanic Origin.
Article in American journal of hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Neighborhood Disinvestment and Racial Disparities in Early Hypertension Onset Among Women.JAMA network open · 2026Article
- Over-the-counter access to combined oral contraceptives for individuals with hypertension: an expert review.American journal of preventive cardiology · 2025Review
- Empowering the Community to Understand Cardiovascular Disease Through a High School Lunch and Learn Series.JACC. Case reports · 2025Article
- Hypertension Management in Women With a Multidisciplinary Approach.Mayo Clinic proceedings · 2025Review
- Uterine fibroids show evidence of shared genetic architecture with blood pressure traits.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025Article
- Burden of hypertensive heart disease among women of childbearing age in global, regional, and national regions from 1990 to 2021 and projection until 2040.Frontiers in global women's health · 2025Article
- Pregnancy-Related Mortality Due to Cardiovascular Conditions: Maternal Mortality Review Committees in 32 U.S. States, 2017 to 2019.JACC. Advances · 2024Article
- Hypertension Prevalence and Control Among U.S. Women of Reproductive Age.American journal of preventive medicine · 2024Article
- Case Report: Angiotensin converting enzyme inhibitors vs. angiotensin receptor blockers in the management of chronic hypertension: a case of lisinopril-induced rhinorrhea.Frontiers in allergy · 2024Article
- Disparities in Hypertension Prevalence, Awareness, Treatment, and Control Among Women Living With and Without HIV in the US South.Open forum infectious diseases · 2024Article
- Menstrual Cycle Irregularity in Adolescence Is Associated With Cardiometabolic Health in Early Adulthood.Journal of the American Heart Association · 2023Article
- Chronic Hypertension in Pregnancy: A Lens Into Cardiovascular Disease Risk and Prevention.Hypertension (Dallas, Tex. : 1979) · 2023Review
- The association between parity and hypertension: a cross-sectional, community-based study.Frontiers in cardiovascular medicine · 2023Article
- An Opportunity to Better Address Hypertension in Women: Self-Measured Blood Pressure Monitoring.Journal of women's health (2002) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTo explore the prevalence, pharmacologic treatment, and control of hypertension among US nonpregnant women of reproductive age by race/Hispanic origin to identify potential gaps in care.
methodsWe pooled data from the 2011 to March 2020 (prepandemic) National Health and Nutrition Examination Survey cycles. Our analytic sample included 4,590 nonpregnant women aged 20-44 years who had at least 1 examiner-measured blood pressure (BP) value. We estimated prevalences and 95% confidence intervals (CIs) of hypertension, pharmacologic treatment, and control based on the 2003 Joint Committee on High Blood Pressure (JNC 7) and the 2017 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines. We evaluated differences by race/Hispanic origin using Rao-Scott chi-square tests.
resultsApplying ACC/AHA guidelines, hypertension prevalence ranged from 14.0% (95% CI: 12.0, 15.9) among Hispanic women to 30.9% (95% CI: 27.8, 34.0) among non-Hispanic Black women. Among women with hypertension, non-Hispanic Black women had the highest eligibility for pharmacological treatment (65.5%, 95% CI: 60.4, 70.5); current use was highest among White women (61.8%, 95% CI: 53.8, 69.9). BP control ranged from 5.2% (95% CI: 1.1, 9.3) among women of another or multiple non-Hispanic races to 18.6% (95% CI: 12.1, 25.0) among Hispanic women.
conclusionsThese findings highlight the importance of monitoring hypertension, pharmacologic treatment, and control by race/Hispanic origin and addressing barriers to equitable hypertension care among women of reproductive age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.